8-K: Athira Pharma Receives Nasdaq Approval for Transfer to Capital Market, Granted Additional Time to Regain Compliance

Athira Pharma receives Nasdaq approval to transfer its listing to the Nasdaq Capital Market and gains an extension to meet minimum bid price requirements.

Summary

• Athira Pharma received approval from Nasdaq to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market.
• This transfer comes after the company failed to maintain the minimum bid price of $1.00 per share for continued listing on the Global Select Market.
• The company has been granted an additional 180-day grace period, until October 13, 2025, to regain compliance with the minimum bid price requirement.
• To regain compliance, the stock price must be at least $1.00 for at least ten consecutive business days during this period.
• If compliance is not achieved, Athira Pharma's common stock will be subject to delisting by Nasdaq.
• The company is seeking stockholder approval for a reverse stock split at its 2025 annual meeting.
• The stock will be transferred to the Nasdaq Capital Market effective April 17, 2025, and will continue to trade under the symbol ATHA.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the company's failure to meet Nasdaq's minimum bid price requirement, but there is a chance for improvement with the extended compliance period and potential reverse stock split.

Positives

• Athira Pharma has been granted an additional 180-day grace period to regain compliance with Nasdaq's minimum bid price requirement.
• The company's stock will continue to trade under the symbol ATHA on the Nasdaq Capital Market.

Negatives

• Athira Pharma failed to maintain the minimum bid price of $1.00 per share, leading to the transfer to the Nasdaq Capital Market.
• Failure to regain compliance within the additional grace period could result in delisting from Nasdaq.

Risks

• Athira Pharma may not be able to meet the minimum bid price requirement by the required compliance date.
• The company may not otherwise meet the requirements for continued listing under the Nasdaq listing rules.
• Nasdaq may not grant the company relief from delisting if necessary.
• A potential reverse stock split may not occur.
• The company's stock price could be negatively impacted if it fails to regain compliance.

Future Outlook

Athira Pharma intends to regain compliance with the minimum bid price requirement and qualify for continued listing on the Nasdaq Capital Market, potentially through a reverse stock split.

Management Comments

• Mark Litton, President and Chief Executive Officer, signed the report on behalf of Athira Pharma.

Industry Context

Many biotech companies, especially those in the development stage, face challenges in maintaining stock prices above the minimum bid price required by major exchanges like Nasdaq. This situation is not uncommon, and companies often explore options like reverse stock splits to address it.

Comparison to Industry Standards

• Other biotech companies facing similar challenges with Nasdaq compliance have included companies like BioLineRx and Diffusion Pharmaceuticals, which have also implemented reverse stock splits to regain compliance.
• The Nasdaq Capital Market provides a venue for smaller companies to maintain a public listing while working to meet the more stringent requirements of the Global Select Market.
• The success of Athira Pharma's efforts to regain compliance will depend on factors such as clinical trial results, regulatory approvals, and overall market conditions, similar to other companies in the biotech sector.

Stakeholder Impact

• Shareholders may experience dilution if a reverse stock split is implemented.
• The company's reputation could be affected by the transfer to the Nasdaq Capital Market.
• Employees may be concerned about the company's financial stability.

Next Steps

• Athira Pharma must regain compliance with the minimum bid price requirement by October 13, 2025.
• The company is seeking stockholder approval for a reverse stock split at its 2025 annual meeting.
• The company will continue to trade on the Nasdaq Capital Market under the symbol ATHA.

Key Dates

Keywords

Nasdaq Capital Market, minimum bid price, listing compliance, reverse stock split, ATHA, delisting, Athira Pharma